Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sera Prognostics Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 2 distinct examiners. The prosecution is distributed across 2 distinct art units, which suggests a broader range of technical subject matter within the Biotechnology & Pharmaceuticals field. This distribution requires the company to manage multiple examination tracks simultaneously.
BORGEEST, CHRISTINA M is the busiest examiner for the portfolio, managing 1 busiest examiner pending action. This represents one of the 2 pending office actions currently active. The distribution across 2 distinct examiners and 2 distinct art units suggests a diverse range of biotechnology applications under review. For the practitioner, this means that the feedback received in one art unit may not necessarily apply to the other. Each pending matter must be handled as a unique case with its own set of technical and procedural challenges. The presence of multiple art units highlights the complexity of the company's current patent prosecution efforts.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BORGEEST, CHRISTINA M | 1 | 55.6% | +21.4% |
| BUNKER, AMY M | 1 | 29.1% | +45.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16919947 | BIOMARKERS AND METHODS FOR PREDICTING PREECLAMPSIA | BUNKER, AMY M | 33d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16919947 | BIOMARKERS AND METHODS FOR PREDICTING PREECLAMPSIA | BUNKER, AMY M | 33d |
| 18592106 | BIOMARKER PAIRS FOR PREDICTING PRETERM BIRTH | BORGEEST, CHRISTINA M | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18592106 | BIOMARKER PAIRS FOR PREDICTING PRETERM BIRTH | BORGEEST, CHRISTINA M | 1675 | §112Other | Non-Final OA | — | Pending | Feb 29, 2024 |
| 16919947 | BIOMARKERS AND METHODS FOR PREDICTING PREECLAMPSIA | BUNKER, AMY M | 1684 | §102 | Final Rejection | 33d | Pending | Jul 02, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial